| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Vß3 Contains a Cell Surface Receptor Site for Thyroid Hormone that Is Linked to Activation of Mitogen-Activated Protein Kinase and Induction of Angiogenesis
Ordway Research Institute (J.J.B., H.-Y.L., L.L., F.B.D., P.J.D.), Stratton Veterans Affairs Medical Center (H.-Y.L., F.B.D., P.J.D.), and Albany College of Pharmacy (S.N.M., S.M.), Albany, New York 12208; and The Wadsworth Center, New York State Department of Health (P.J.D.), Albany, New York 12201
Address all correspondence and requests for reprints to: Dr. Paul J. Davis, Ordway Research Institute, 150 New Scotland Avenue, Albany, New York 12208. E-mail: pdavis{at}ordwayresearch.org.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Vß3 is a heterodimeric plasma membrane protein whose several extracellular matrix protein ligands contain an RGD recognition sequence. This study identifies integrin Vß3 as a cell surface receptor for thyroid hormone [L-T4 (T4)] and as the initiation site for T4-induced activation of intracellular signaling cascades. Integrin Vß3 dissociably binds radiolabeled T4 with high affinity, and this binding is displaced by tetraiodothyroacetic acid, Vß3 antibodies, and an integrin RGD recognition site peptide. CV-1 cells lack nuclear thyroid hormone receptor, but express plasma membrane Vß3; treatment of these cells with physiological concentrations of T4 activates the MAPK pathway, an effect inhibited by tetraiodothyroacetic acid, RGD peptide, and Vß3 antibodies. Inhibitors of T4 binding to the integrin also block the MAPK-mediated proangiogenic action of T4. T4-induced phosphorylation of MAPK is inhibited by small interfering RNA knockdown of V and ß3. These findings suggest that T4 binds to Vß3 near the RGD recognition site and show that hormone-binding to Vß3 has physiological consequences. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Our laboratory has shown in the CV-1 monkey fibroblast cell line, which lacks functional TR, and in other cells that T4 activates the MAPK (ERK1/2) signaling cascade and promotes the phosphorylation and nuclear translocation of MAPK as early as 10 min after application of a physiological concentration of T4 (6, 19). In nuclear fractions of thyroid hormone-treated cells, we have described complexes of activated MAPK and transactivator nucleoproteins that are substrates for the serine kinase activity of MAPK. These proteins include signal transducer and activator of transcription-1 (STAT-1) (6), STAT3 (19), p53 (20), estrogen receptor- (21), and, in cells containing TR, the nuclear thyroid hormone receptor for T3 (TRß1) (22). Thyroid hormone-directed MAPK-mediated phosphorylation of these proteins enhances their transcriptional capabilities (6, 19, 20, 21, 22). The effects of T4-induced MAPK activation are blocked by inhibitors of the MAPK signal transduction pathway and by tetraiodothyroacetic acid (tetrac) (6, 19, 20, 21, 22), a thyroid hormone analog that inhibits T4 binding to the cell surface (23). Thyroid hormone-activated MAPK may also act locally at the plasma membrane, e.g. on the Na+/H+ antiporter (10), rather than when translocated to the cell nucleus. A cell surface receptor for T4 that is linked to activation of the MAPK cascade has not previously been identified.
Integrins are a family of transmembrane glycoproteins that form noncovalent heterodimers. Extracellular domains of the integrins interact with a variety of ligands (24), including extracellular matrix glycoproteins, and the intracellular domain is linked to the cytoskeleton (25). Thyroid hormone was shown a decade ago to influence the interaction of integrin with the extracellular matrix protein, laminin (26), but the mechanism of the interaction was not known. Integrin Vß3 has a large number of extracellular protein ligands, including growth factors and extracellular matrix proteins, and upon ligand binding can activate the MAPK cascade (27, 28). Several of the integrins contain an RGD recognition site that is important to the binding of matrix and other extracellular proteins that contain an Arg-Gly-Asp sequence (24). Recently, Hoffman et al. (29) showed that blocking the integrin RGD site prevented bone resorption stimulated by T4. These observations raised the possibility that the cell surface receptor for T4 might be located on an integrin.
Using the chick chorioallantoic membrane (CAM) assay, we have demonstrated that T4 treatment results in increased angiogenesis, i.e. an increased number of blood vessel branch points, that is independent of T4 conversion to T3 (30). The mechanism of T4-induced angiogenesis requires MAPK activity, is inhibited by tetrac, and is reproduced by T4-agarose. These observations coupled with the ability of an Vß3 antagonist to inhibit thyroid hormone-induced bone resorption (29) supported the possibility that Vß3 is a cell surface receptor for T4.
We show in this report that integrin Vß3 specifically binds T4, that the integrin and integrin-thyroid hormone complex are required for activation of MAPK by physiological concentrations of T4, and that occlusion by antagonists of the RGD site on Vß3 inhibits T4-induced, MAPK-mediated angiogenesis in the CAM assay. The combination of specific binding of hormone by this integrin and the functional consequences of in vivo interference with formation of the Vß3-T4 complex support a role for the integrin as a cell surface thyroid hormone receptor.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
98% pure by HPLC), T3, tetrac, propylthiouracil, RGD-containing peptides, and RGE-containing peptides were purchased from Sigma-Aldrich Corp. (St. Louis, MO). Monoclonal antibodies to Vß3 (SC7312) and -tubulin (E9) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Normal mouse IgG and horseradish peroxidase-conjugated goat antirabbit Ig were purchased from DakoCytomation (Carpinteria, CA). Monoclonal antibodies to Vß3 (LM609) and Vß5 (P1F6) as well as purified Vß3 were purchased from Chemicon International (Temecula, CA). L-[125I]T4 (specific activity, 1250 µCi/µg) was obtained from PerkinElmer (Boston, MA). V, ß3, and scrambled negative control small interfering RNA (siRNAs) were all purchased from Ambion, Inc. (Austin, TX).
Cell culture
The African green monkey fibroblast cell line, CV-1 (American Type Culture Collection, Manassas, VA), which lacks the nuclear receptor for thyroid hormone, was plated at 5000 cells/cm2, maintained in DMEM, supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine. All culture reagents were purchased from Invitrogen Life Technologies, Inc. (Carlsbad, CA). Cultures were maintained in a 37 C humidified chamber with 5% CO2. The medium was changed every 3 d, and the cell lines were passaged at 80% confluence. For experimental treatment, cells were plated in 10-cm cell culture dishes (Corning, Inc., Corning, NY) and allowed to grow for 24 h in 10% FBS-containing medium. The cells were then rinsed twice with PBS and fed with serum-free DMEM supplemented with penicillin, streptomycin, and HEPES. After 48-h incubation in serum-free medium, the cells were treated with a vehicle control [final concentration of 0.04 N KOH with 0.4% polyethylene glycol (vol/vol)] or T4 (diluted to its final concentration from a 10–3 M stock, using the vehicle as a diluent) for 30 min. Media were then collected, and free T4 levels were determined by enzyme immunoassays. All experimental cultures were treated with 1 mM propylthiouracil to prevent the 5'-monodeiodination of T4 into T3. Cultures incubated with 10–7 M total T4 have 10–9 to 10–10 M free T4, consistent with normal physiological levels. After treatment, the cells were harvested, and nuclear proteins were prepared as previously described (6).
Transient transfections with siRNA
CV-1 cells were plated in 10-cm dishes (150,000 cells/dish) and incubated for 24 h in DMEM supplemented with 10% FBS. The cells were rinsed in Opti-MEM (Ambion, Inc.) and transfected with siRNA (100 nM final concentration) to V, ß3, or V and ß3 together using siPORT (Ambion, Inc.) according to the manufacturer’s directions. Additional sets of CV-1 cells were transfected with a scrambled siRNA to serve as a negative control. Four hours after transfection, 7 ml 10% FBS-containing medium was added to the dishes, and the cultures were allowed to incubate overnight. The cells were then rinsed with PBS and placed in serum-free DMEM for 48 h before treatment with T4.
RNA isolation and RT-PCR
Total RNA was extracted from cell cultures 72 h after transfection using the RNeasy kit from Qiagen (Valencia, CA) according to the manufacturer’s instructions. Two hundred nanograms of total RNA were reverse transcribed using the Access RT-PCR system (Promega Corp., Madison, WI) according to the manufacturer’s directions. Primers were based on published species-specific sequences: V (accession no. NM_002210): forward, 5'-TGGGATTGTGGAAGGAG; reverse, 5'-AAATCCCTGTCCATCAGCAT (319-bp product); ß3 (NM_000212): forward, 5'-GTGTGAGTGCTCAGAGGAG; reverse, 5'-CTGACTCAATCTCGTCACGG (515-bp product); and glyceraldehyde-3-phosphate dehydrogenase (AF261085): forward, 5'-GTCAGTGGTGGACCTGACCT; reverse, 5'-TGAGCTTGACAAAGTGGTCG (212-bp product). RT-PCR was performed in the Flexigene thermal cycler (TECHNE, Burlington, NJ). After a 2-min incubation at 95 C, 25 cycles of the following steps were performed: denaturation at 94 C for 1 min, annealing at 57 C for 1 min, and extension for 1 min at 68 C. The PCR products were visualized on a 1.8% (wt/vol) agarose gel stained with ethidium bromide.
Western blotting
Nuclear proteins were harvested as previously described (6, 19, 31). Aliquots of nuclear proteins (10 µg/lane) were mixed with Laemmli sample buffer and separated by SDS-PAGE (10% resolving gel), then transferred to nitrocellulose membranes. After blocking with 5% nonfat milk in Tris-buffered saline containing 1% Tween 20 (TBST) for 30 min, the membranes were incubated with a 1:1000 dilution of a monoclonal antibody (mAb) to phosphorylated p44/42 MAPK (Cell Signaling Technology, Beverley, MA) in TBST with 5% milk overnight at 4 C. After three 10-min washes in TBST, the membranes were incubated with horseradish peroxidase-conjugated goat antirabbit Ig (1:1000 dilution; DakoCytomation, Carpinteria, CA) in TBST with 5% milk for 1 h at room temperature. The membranes were washed three times for 5 min each time in TBST, and immunoreactive proteins were detected by chemiluminescence (ECL, Amersham Biosciences, Arlington Heights, IL). Band intensity was determined using the VersaDoc 5000 Imaging system (Bio-Rad Laboratories, Hercules, CA).
Radioligand binding assay
The assay was performed following the basic-native gel protocol from the Protein Purification Facility (www.ls.huji.ac.il/
purification/Protocols/PAGE_Basic.html). All test compounds were diluted to their final concentration in 0.04 N KOH with 0.4% polyethylene glycol to ensure that the effect was independent of the solvent used. Two micrograms of purified Vß3 (stock concentration, 0.3–0.5 µg/µl) were mixed with the indicated concentrations of test compounds and allowed to incubate for 30 min at room temperature. [125I]T4 (2 µCi) was then added, and the mixture was allowed to incubate an additional 30 min at room temperature. The samples were mixed with sample buffer [50% glycerol, 0.1 M Tris-HCl (pH 6.8), and bromophenol blue] and run out on a 5% basic-native gel for 24 h at 45 mA in the cold. The apparatus was disassembled, and the gels were placed on filter paper, wrapped in plastic wrap, and exposed to film. Band intensity was determined with the VersaDoc 5000 Imaging system.
The dissociation constant (Kd) and EC50 were determined using the PRISM software bundle (GraphPad, San Diego, CA). Kd was determined by nonlinear regression, using the programmed homologous competitive binding curve with one class of binding sites equation. Nonspecific binding was held constant at 15. The constant Hot nM was set at 0.13, as determined by the equation Hot nM = hot cpm/(specific activity x incubation volume x 1000). EC50 was determined using nonlinear regression with the programmed equation for sigmoidal dose response.
Chick CAM assay
Ten-day-old chick embryos were purchased from SPAFAS (Preston, CT) and were incubated at 37 C with 55% relative humidity. Chick CAM assays were performed as previously described (30, 32, 33). Briefly, a hypodermic needle was used to make a small hole in the blunt end of the egg, and a second hole was made on the broad side of the egg, directly over an avascular portion of the embryonic membrane. Mild suction was applied to the first hole to displace the air sac and drop the CAM away from the shell. Using a Dremel model craft drill (Dremel, Racine, WI), an approximately 1.0-cm2 window was cut in the shell over the false air sac, allowing access to the CAM. Sterile disks of no. 1 filter paper (Whatman, Clifton, NJ) were pretreated with 3 mg/ml cortisone acetate and 1 mM propylthiouracil and air dried under sterile conditions. Thyroid hormone, control solvents, and the mAb LM609 were applied to the disks and subsequently dried. The disks were then suspended in PBS and placed on growing CAMs. After incubation for 3 d, the CAM beneath the filter disk was resected and rinsed with PBS. Each membrane was placed in a 35-mm petri dish and examined under an SV6 stereomicroscope at x50 magnification. Digital images were captured and analyzed with Image-Pro software (Media Cybernetics, Silver Spring, MD). The number of vessel branch points contained in a circular region equal to the filter disk was counted. One image from each of eight to 10 CAM preparations for each treatment condition was counted, and in addition, each experiment was performed three times.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Vß3 integrinVß3 integrin, 2 µg commercially available purified protein were incubated with [125I]T4, and the mixture was run out on a nondenaturing polyacrylamide gel. Vß3 Bound radiolabeled T4, and this interaction was diminished by unlabeled T4, which was added to Vß3 before the [125I]T4 incubation, in a concentration-dependent manner (Fig. 1
). The addition of unlabeled T4 reduced binding of integrin to the radiolabeled ligand by 13% at a total T4 concentration of 10–7 M (3 x 10–10 M free T4) and by 58% at a total concentration of 10–6 M (1.6 x 10–9 M free), and inhibition of binding was maximal (85%) with 10–5 M unlabeled T4 (2.1 x 10–8 M free). Using nonlinear regression, the interaction of Vß3 with free T4 was determined to have a Kd of 333 pM and an EC50 of 371 pM. Unlabeled T3 was less effective in displacing [125I]T4 binding to Vß3, reducing the signal by 28% at 10–4 M total T3. Similar results were observed when binding assays were performed with addition of the radiolabeled ligand to the integrin for 30 min before addition of unlabeled T4 (data not shown).
|
Vß3 is blocked by tetrac, RGD peptide, and integrin antibodyVß3, the association of T4 and Vß3 was reduced by 38% in the presence of 10–7 M tetrac and by 90% with 10–5 M tetrac (Fig. 2). To determine the specificity of the interaction, an RGD peptide, which binds to the extracellular matrix binding site on Vß3, and an RGE peptide, which has a glutamic acid residue instead of an aspartic acid residue and thus does not bind Vß3, were added in an attempt to displace T4 from binding with the integrin. Application of an RGD peptide, but not an RGE peptide, reduced the interaction of [125I]T4 with Vß3 in a dose-dependent manner (Fig. 2).
|
Vß3, antibodies to Vß3 or Vß5 were added to purified Vß3 before addition of [125I]T4. Addition of 1 µg/ml Vß3 mAb LM609 reduced complex formation between the integrin and T4 by 52% compared with untreated control samples. Increasing the amount of LM609 to 2, 4, and 8 µg/ml diminished band intensity by 64%, 63%, and 81%, respectively (Fig. 3). Similar results were observed when a different Vß3 mAb, SC7312, was incubated with the integrin. SC7312 reduced the ability of T4 to bind Vß3 by 20% with 1 µg/ml antibody present, 46% with 2 µg, 47% with 4 µg, and 59% with 8 µg/ml antibody present. Incubation with mAbs to V and ß3 separately did not affect [125I]T4 binding to Vß3 (data not shown), suggesting that the association requires the binding pocket generated from the heterodimeric complex of Vß3 and not necessarily a specific region on either monomer. To verify that the reduction in band intensity was due to specific recognition of Vß3 by antibodies, purified Vß3 was incubated with a mAb to Vß5 (P1F6) or mouse IgG before addition of [125I]T4, neither of which influenced complex formation between the integrin and radioligand (Fig. 3).
|
Vß3). Preincubation of CV-1 cells with the indicated concentrations of Vß3 antagonists for 16 h reduced the ability of T4 to induce MAPK activation and translocation. Application of an RGD peptide at 10–8 and 10–7 M had a minimal effect on MAPK activation. However, 10–6 M RGD peptide inhibited MAPK phosphorylation by 62% compared with control cultures, and activation was reduced maximally when 10–5 M RGD (85% reduction) and 10–4 M RGD (87% reduction) were present in the culture medium. Addition of the nonspecific RGE peptide to the culture medium had no effect on MAPK phosphorylation and nuclear translocation after T4 treatment in CV-1 cells.
|
). The inhibition increased to 97% when 10–4 M tetrac was added to the culture medium for 16 h before the application of T4. Addition of Vß3 mAb LM609 to the culture medium 16 h before stimulation with T4 also reduced T4-induced MAPK activation. LM609 at 0.01 and 0.001 µg/ml culture medium did not affect MAPK activation after T4 treatment. Increasing the concentration of antibody in the culture medium to 0.1, 1, and 10 µg/ml reduced levels of phosphorylated MAPK found in the nuclear fractions of the cells by 29%, 80%, and 88%, respectively, compared with cells treated with T4 alone.
CV-1 cells were transiently transfected with siRNA to V, ß3, or both V and ß3 and allowed to recover for 16 h before being placed in serum-free medium. After T4 treatment for 30 min, the cells were harvested, and either nuclear protein or RNA was extracted. Figure 5A demonstrates the specificity of each siRNA for the target integrin subunit. CV-1 cells transfected with either the V siRNA or both V and ß3 siRNAs showed 87% and 78% decreases, respectively, in V subunit RT-PCR products, but there was no difference in V mRNA expression when cells were transfected with the siRNA specific for ß3 or when exposed to the transfection reagent in the absence of exogenous siRNA. Similarly, cells transfected with ß3 siRNA had reduced levels of ß3 mRNA by 64% compared with the parental cells, but relatively unchanged levels of V siRNA. As expected, the addition of T4 for 30 min did not alter mRNA levels for either V or ß3 regardless of the siRNA transfected into the cells.
|
V and ß3, either individually or in combination (Fig. 5B). CV-1 cells treated with scrambled negative control siRNA had slightly elevated levels of T4-induced activated MAPK compared with the parental cell line. Cells exposed to the transfection reagent alone displayed similar levels and patterns of MAPK phosphorylation as nontransfected CV-1 cells (data not shown). When either V siRNA or ß3 siRNA, alone or in combination, was transfected into CV-1 cells, the level of phosphorylated MAPK in vehicle-treated cultures was elevated, but the ability of T4 to induce an additional elevation in activated MAPK levels was inhibited.
Hormone-induced angiogenesis is blocked by antibody to Vß3
Angiogenesis is stimulated in the CAM assay by application of physiological concentrations of T4 (Fig. 6A; summarized in Fig. 6B). T4 (10–7 M) placed on the CAM filter disk induced blood vessel branch formation by 2.3-fold (P < 0.001) compared with PBS-treated membranes. We have shown previously that propylthiouracil, which prevents the conversion of T4 to T3, has no effect on angiogenesis caused by T4 in the CAM model (30). The addition of a mAb, LM609 (10 µg/filter disk), directed against Vß3, inhibited the proangiogenic response to T4.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Using purified integrin, we report that a member of the heterodimeric plasma membrane integrin protein family, integrin Vß3, binds T4 and that this interaction is perturbed by Vß3 antagonists. Radioligand binding studies revealed that purified Vß3 binds T4 with high affinity (EC50, 371 pM) and appears to bind T4 preferentially over T3. This is consistent with previous reports that show MAPK activation and nuclear translocation (6, 20, 22) as well as hormone-induced angiogenesis by T4 compared with T3. Integrin Vß3 antagonists inhibit binding of T4 to the integrin and, importantly, prevent outside-in activation by T4 of the MAPK signaling cascade. This functional consequence, MAPK activation, of hormone binding to the integrin together with inhibition of the MAPK-dependent proangiogenic action of thyroid hormone by integrin Vß3 antagonists allow us to describe the integrin as a receptor for iodothyronine. It should be noted that 3-iodothyronamine, a thyroid hormone derivative, has recently been shown by Scanlan et al. (37) to bind to a trace amine receptor, but the actions of this analog, interestingly, are antithetic to those of T4 and T3.
The traditional ligands of integrins are proteins. That a small molecule, thyroid hormone, is also a ligand of an integrin is a novel finding. We have observed recently that another small molecule, resveratrol, a polyphenol with some estrogenic activity, binds to integrin Vß3 with a functional cellular consequence, apoptosis, different from those that result from the binding of thyroid hormone (Lin, H.-Y., L. Lansing, P. J. Davis, unpublished observations). The exact site on the integrin at which T4 binds is not yet known, but the evidence we present here suggests that the protein-ligand interaction occurs at or near the RGD binding groove (38, 39) of the heterodimeric integrin. It is possible, however, that Vß3 binds T4 elsewhere on the protein, and occupation of the RGD recognition site by tetrac or RGD-containing peptides allosterically blocks the T4-binding site or causes a conformational change within the integrin that renders the T4 site unavailable.
We speculate that the modulation by T4 of the laminin-integrin interaction of astrocytes described by Farwell et al. (26) may be a consequence of binding of the hormone to the integrin. This interaction was shown by Farwell et al. (26) to be subject to disruption by RGD peptide. The possibility thus exists that at the cell exterior, thyroid hormone may affect the liganding by integrin Vß3 of extracellular matrix proteins in addition to laminin.
Actions of T4 that are nongenomic in mechanism have been well documented in recent years (6, 7, 10, 40). A number of these activities are MAPK mediated. We have shown that initial steps in activation of the MAPK cascade by thyroid hormone, including activation of protein kinase C, are sensitive to guanosine-5'-O-(3-thiotriphosphate) 
S and pertussis toxin; this indicates that the plasma membrane receptor for thyroid hormone is G protein sensitive (6). It should be noted that certain cellular functions mediated by integrin Vß3 have been shown by others to be G protein modulated (41). For example, site-directed mutagenesis of the RGD binding domain abolishes the ability of the nucleotide receptor P2Y2 to activate Go, whereas the activation of Gq was not affected (41). Wang et al. (42) demonstrated that an integrin-associated protein, integrin-associated protein/CD47, induced smooth muscle cell migration via Gi-mediated inhibition of MAPK activation.
In addition to linking the binding of T4 by integrin Vß3 to activation of a specific intracellular signal transduction pathway, we also show that liganding of the hormone by the integrin is critical to induction by T4 of MAPK-dependent angiogenesis. In the CAM model, significant vessel growth occurs after 48–72 h of T4 treatment, indicating that the plasma membrane effects of T4 can result in complex transcriptional changes. Thus, what is initiated as a nongenomic action of the hormone, transduction of the cell surface T4 signal, interfaces with genomic effects of the hormone that culminate in neovascularization. We have previously described interfaces of nongenomic and genomic actions of thyroid hormone, e.g. MAPK-dependent phosphorylation at Ser142 of TRß1 that is initiated at the cell surface by T4 and that results in shedding by TR of corepressor proteins and recruitment of coactivators (43). We have also shown that T4 stimulates growth of C-6 glial cells by a MAPK-dependent mechanism that is inhibited by RGD peptide (44), and that thyroid hormone causes MAPK-mediated serine phosphorylation of the nuclear estrogen receptor in MCF-7 cells (21) by a process we now know to be inhibitable by an RGD peptide (Lansing, L., and H.-Y. Lin, unpublished observations). These findings in several cell lines all support the participation of the integrin in functional responses of cells to thyroid hormone.
Identification of Vß3 as a membrane receptor for thyroid hormone permits speculation about clinical significance of the interaction of the integrin and the hormone and the downstream consequence of angiogenesis. For example, Vß3 is overexpressed in many tumors, and this overexpression appears to play a role in tumor invasion and growth (45, 46, 47). Relatively constant circulating levels of thyroid hormone may facilitate tumor-associated angiogenesis. In addition to demonstrating the proangiogenic action of T4 in the CAM model here and previously (30), we have recently found that human dermal microvascular endothelial cells also form new blood vessels when exposed to thyroid hormone (Mousa, S. A., F. B. Davis, and P. J. Davis, unpublished observations). Local delivery of Vß3 antagonists or tetrac around tumor cells might inhibit thyroid hormone-stimulated angiogenesis. Although tetrac lacks many of the biological activities of thyroid hormone, it does gain access to the interior of certain cells (48). Anchoring of tetrac or specific RGD antagonists to nonimmunogenic substrates (agarose or polymers) would exclude the possibility that the compounds could cross the plasma membrane, yet retain, as shown in this study, the ability to prevent T4-induced angiogenesis. Thus, agarose-T4, used in previous studies (6, 22, 30), is a prototype for a new family of thyroid hormone analogs that have specific cellular effects, but do not gain access to the cell interior.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
First Published Online March 31, 2005
Abbreviations: CAM, Chorioallantoic membrane; FBS, fetal bovine serum; mAb, monoclonal antibody; siRNA, small interfering RNA; STAT, signal transducer and activator of transcription; TBST, Tris-buffered saline containing 1% Tween 20; tetrac, tetraiodothyroacetic acid; TR, thyroid hormone receptor.
Received January 26, 2005.
Accepted for publication March 21, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
v integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 162:933–943vß3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 64:977–984vß3 And vß5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6:105–119[CrossRef][Medline]
Vß3 in complex with an Arg-Gly-Asp ligand. Science 296:151–155Vß3 integrins and is required for Go-mediated signal transduction. J Cell Biol 153:491–5012ß1-dependent chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases. J Cell Biol 147:389–400vß3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 62:2824–2833v integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110:326–335[CrossRef][Medline]
This article has been cited by other articles:
 |
|
 |
|
  N. Kobayashi, M. Orisaka, M. Cao, F. Kotsuji, A. Leader, N. Sakuragi, and B. K. Tsang Growth Differentiation Factor-9 Mediates Follicle-Stimulating Hormone-Thyroid Hormone Interaction in the Regulation of Rat Preantral Follicular Development Endocrinology, December 1, 2009; 150(12): 5566 - 5574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Samson The search for the membrane thyroid hormone receptor Am J Physiol Endocrinol Metab, December 1, 2009; 297(6): E1237 - E1237. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Davis, F. B. Davis, H.-Y. Lin, S. A. Mousa, M. Zhou, and M. K. Luidens Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor Am J Physiol Endocrinol Metab, December 1, 2009; 297(6): E1238 - E1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. YALCIN, D.J. BHARALI, L. LANSING, E. DYSKIN, S.S. MOUSA, A. HERCBERGS, F.B. DAVIS, P.J. DAVIS, and S.A. MOUSA Tetraidothyroacetic Acid (Tetrac) and Tetrac Nanoparticles Inhibit Growth of Human Renal Cell Carcinoma Xenografts Anticancer Res, October 1, 2009; 29(10): 3825 - 3831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Niederkinkhaus, R. Marx, G. Hoffmann, and I. D. Dietzel Thyroid Hormone (T3)-Induced Up-Regulation of Voltage-Activated Sodium Current in Cultured Postnatal Hippocampal Neurons Requires Secretion of Soluble Factors from Glial Cells Mol. Endocrinol., September 1, 2009; 23(9): 1494 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Bai, J. Li, L. Zhou, and X. Li Influence of the menstrual cycle on nonlinear properties of heart rate variability in young women Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H765 - H774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Lin, M. Sun, H.-Y. Tang, C. Lin, M. K. Luidens, S. A. Mousa, S. Incerpi, G. L. Drusano, F. B. Davis, and P. J. Davis L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase Am J Physiol Cell Physiol, May 1, 2009; 296(5): C980 - C991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bhargava, J. Lei, and D. H. Ingbar Nongenomic actions of L-thyroxine and 3,5,3'-triiodo-L-thyronine. Focus on "L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase" Am J Physiol Cell Physiol, May 1, 2009; 296(5): C977 - C979. [Full Text] [PDF]
|
|
|
|
|
|
O. Araki, H. Ying, X. G. Zhu, M. C. Willingham, and S. Y. Cheng Distinct Dysregulation of Lipid Metabolism by Unliganded Thyroid Hormone Receptor Isoforms Mol. Endocrinol., March 1, 2009; 23(3): 308 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Scapin, S. Leoni, S. Spagnuolo, A. M. Fiore, and S. Incerpi Short-term effects of thyroid hormones on Na+-K+-ATPase activity of chick embryo hepatocytes during development: focus on signal transduction Am J Physiol Cell Physiol, January 1, 2009; 296(1): C4 - C12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lei, M. Bhargava, and D. H. Ingbar Cell-specific signal transduction pathways regulating Na+-K+-ATPase. Focus on "Short-term effects of thyroid hormones on the Na+-K+-ATPase activity of chick embryo hepatocytes during development: focus on signal transduction" Am J Physiol Cell Physiol, January 1, 2009; 296(1): C1 - C3. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Yonkers and A. B. Ribera Sensory Neuron Sodium Current Requires Nongenomic Actions of Thyroid Hormone During Development J Neurophysiol, November 1, 2008; 100(5): 2719 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Levin Rapid signaling by steroid receptors Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1425 - R1430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Radenne, M. Akpa, C. Martel, S. Sawadogo, D. Mauvoisin, and C. Mounier Hepatic regulation of fatty acid synthase by insulin and T3: evidence for T3 genomic and nongenomic actions Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E884 - E894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Benvenuti, P Luciani, I Cellai, C Deledda, S Baglioni, R Saccardi, S Urbani, F Francini, R Squecco, C Giuliani, et al. Thyroid hormones promote cell differentiation and up-regulate the expression of the seladin-1 gene in in vitro models of human neuronal precursors J. Endocrinol., May 1, 2008; 197(2): 437 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Mascanfroni, M. d. M. Montesinos, S. Susperreguy, L. Cervi, J. M. Ilarregui, V. D. Ramseyer, A. M. Masini-Repiso, H. M. Targovnik, G. A. Rabinovich, and C. G. Pellizas Control of dendritic cell maturation and function by triiodothyronine FASEB J, April 1, 2008; 22(4): 1032 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lei, C. N. Mariash, M. Bhargava, E. V. Wattenberg, and D. H. Ingbar T3 increases Na-K-ATPase activity via a MAPK/ERK1/2-dependent pathway in rat adult alveolar epithelial cells Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L749 - L754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Scarlett, M P Parsons, P L Hanson, K K Sidhu, T P Milligan, and J M Burrin Thyroid hormone stimulation of extracellular signal-regulated kinase and cell proliferation in human osteoblast-like cells is initiated at integrin {alpha}V{beta}3 J. Endocrinol., March 1, 2008; 196(3): 509 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Conrad, J. M. Strafuss, M. D. Wittman, S. Conway, and G. W. Conrad Thyroxine Increases the Rate but Does Not Alter the Pattern of Innervation during Embryonic Chick Corneal Development Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 139 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Irrcher, D. R. Walkinshaw, T. E. Sheehan, and D. A. Hood Thyroid hormone (T3) rapidly activates p38 and AMPK in skeletal muscle in vivo J Appl Physiol, January 1, 2008; 104(1): 178 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Lin, H.-Y. Tang, T. Keating, Y.-H. Wu, A. Shih, D. Hammond, M. Sun, A. Hercbergs, F. B. Davis, and P. J. Davis Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated Carcinogenesis, January 1, 2008; 29(1): 62 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Hammes and E. R. Levin Extranuclear Steroid Receptors: Nature and Actions Endocr. Rev., December 1, 2007; 28(7): 726 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Kuzman, T. D. O'Connell, and A. M. Gerdes Rapamycin Prevents Thyroid Hormone-Induced Cardiac Hypertrophy Endocrinology, July 1, 2007; 148(7): 3477 - 3484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hercbergs and P. Davis Hypothyroidism in the Patient With Cancer: How Much Thyroid Supplementation Is "Safe"? Arch Otolaryngol Head Neck Surg, June 1, 2007; 133(6): 625 - 626. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Verga Falzacappa, E. Petrucci, V. Patriarca, S. Michienzi, A. Stigliano, E. Brunetti, V. Toscano, and S. Misiti Thyroid hormone receptor TR{beta}1 mediates Akt activation by T3 in pancreatic {beta} cells J. Mol. Endocrinol., February 1, 2007; 38(2): 221 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Flamant, K. Gauthier, and J. Samarut Thyroid Hormones Signaling Is Getting More Complex: STORMs Are Coming Mol. Endocrinol., February 1, 2007; 21(2): 321 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Germain, B. Staels, C. Dacquet, M. Spedding, and V. Laudet Overview of Nomenclature of Nuclear Receptors Pharmacol. Rev., December 1, 2006; 58(4): 685 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Acconcia, B. Manavathi, J. Mascarenhas, A. H. Talukder, G. Mills, and R. Kumar An Inherent Role of Integrin-Linked Kinase-Estrogen Receptor {alpha} Interaction in Cell Migration. Cancer Res., November 15, 2006; 66(22): 11030 - 11038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Lin, L. Lansing, J.-M. Merillon, F. B. Davis, H.-Y. Tang, A. Shih, X. Vitrac, S. Krisa, T. Keating, H. J. Cao, et al. Integrin {alpha}V{beta}3 contains a receptor site for resveratrol FASEB J, August 1, 2006; 20(10): 1742 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. B. Davis, H.-Y. Tang, A. Shih, T. Keating, L. Lansing, A. Hercbergs, R. A. Fenstermaker, A. Mousa, S. A. Mousa, P. J. Davis, et al. Acting via a Cell Surface Receptor, Thyroid Hormone Is a Growth Factor for Glioma Cells. Cancer Res., July 15, 2006; 66(14): 7270 - 7275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Yen Thyroid hormones and 3,5-diiodothyropropionic Acid: new keys for new locks. Endocrinology, April 1, 2006; 147(4): 1598 - 1601. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mousa, L. O'Connor, F. B. Davis, and P. J. Davis Proangiogenesis Action of the Thyroid Hormone Analog 3,5-Diiodothyropropionic Acid (DITPA) Is Initiated at the Cell Surface and Is Integrin Mediated Endocrinology, April 1, 2006; 147(4): 1602 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Moeller, A. M. Dumitrescu, and S. Refetoff Cytosolic Action of Thyroid Hormone Leads to Induction of Hypoxia-Inducible Factor-1{alpha} and Glycolytic Genes Mol. Endocrinol., December 1, 2005; 19(12): 2955 - 2963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Incerpi Thyroid Hormones: Rapid Reply by Surface Delivery Only Endocrinology, July 1, 2005; 146(7): 2861 - 2863. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
